LCTX vs RLAY โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
LCTX Captures Institutional Edge (2โ2 Pillars ยท 6โ4 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Lineage Cell Therapeutics, Inc. (LCTX) driven by superior Valuation, Growth & Margin while RLAY counters with relative strength in Momentum & Technical, Options & Structure. Fundamentally, LCTX trades at 30.7x Forward P/E with -280.3% operating margin (-61.0% YoY revenue) versus RLAY at N/M Forward P/E and -3094.6% operating margin (-48.3% YoY). In options structure, LCTX sits in BREAKDOWN (100th %ile IV; Dealer Gamma Walls on Pro) against RLAY sits in CONSOLIDATION (6th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | LCTX Revenue | RLAY Revenue | LCTX Op. Margin | RLAY Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | $0M | N/A | -837.9% | N/A | LCTX |
| FY2019 | $0M | N/A | -1106.0% | N/A | LCTX |
| FY2020 | $0M | $80M | -1448.4% | -67.5% | RLAY |
| FY2021 | $0M | $0M | -1133.6% | -12040.2% | LCTX |
| FY2022 | $10M | $0M | -153.2% | -21670.9% | LCTX |
| FY2023 | $10M | $30M | -276.5% | -1460.1% | LCTX |
| FY2024 | $10M | $10M | -226.1% | -3722.1% | LCTX |
| FY2025 | $10M | $20M | -251.6% | -1971.6% | LCTX |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | LCTX | RLAY | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $212.1M | $3.6B | Larger Scale | RLAY |
| Trailing P/E Ratio Valuation | 30.7x | N/M | Lower Multiple | LCTX |
| Forward P/E Ratio Valuation | 30.7x | N/M | Lower Multiple | LCTX |
| Revenue Growth (YoY) Growth | -61.0% | -48.3% | Higher Growth | RLAY |
| Operating Margin (TTM) Profitability | -280.3% | -3094.6% | Higher Margin | LCTX |
| Net Profit Margin Profitability | 16.2% | 0.0% | Higher Margin | LCTX |
| Return on Equity (ROE) Capital Efficiency | 4.3% | -41.2% | Higher ROE | LCTX |
| 52-Week Range Position Momentum | 4% ($1โ$2) | 64% ($6โ$21) | Stronger Trend | RLAY |
| Beta / 30D Volatility Risk Regime | 1.36ฮฒ ยท 79% Vol | 1.74ฮฒ ยท 74% Vol | Lower Realized Risk | RLAY |
| Unified Institutional Score Composite Signal | 58.9 / 100 (HOLD) | 47.3 / 100 (HOLD) | Higher Composite | LCTX |